Garden State Heart Care — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$6,951	1
2024	Research	$10,850	1
2023	Research	$11,913	1
2020	Research	$6,055	2
2019	Research	$26,751	1

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $29,714 3 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $27,806 2 payments
Bayer HealthCare Pharmaceuticals Inc. $5,000 1 payment

Studies the money was for Research payments · program years 2019–2025

Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $29,714 3 payments
GLORIA AF Registry Phase II III Core $27,806 2 payments
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) $5,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.